Bevacizumab Beyond Progression: Does This Make Sense?

被引：25

作者：

Ellis, Lee M. ^{[1
]}

Haller, Daniel G. ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Penn, Philadelphia, PA 19104 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 33期

关键词：

D O I：

10.1200/JCO.2008.17.4540

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5313 / 5315

页数：3

共 13 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2] Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells [J].

Dallas, Nikolaos A. ;

Fan, Fan ;

Gray, Michael J. ;

Van Buren, George, II ;

Lim, Sherry J. ;

Xia, Ling ;

Ellis, Lee M. .

CANCER AND METASTASIS REVIEWS, 2007, 26 (3-4) :433-441

[3] VEGF-targeted therapy: mechanisms of anti-tumour activity [J].

Ellis, Lee M. ;

Hicklin, Daniel J. .

NATURE REVIEWS CANCER, 2008, 8 (08) :579-591

[4] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

[5] Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment [J].

Grothey, A ;

Sargent, D ;

Goldberg, RM ;

Schmoll, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1209-1214

[6] Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) [J].

Grothey, Axel ;

Sugrue, Mary M. ;

Purdie, David M. ;

Dong, Wei ;

Sargent, Daniel ;

Hedrick, Eric ;

Kozloff, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5326-5334

[7] Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab [J].

Ince, WL ;

Jubb, AM ;

Holden, SN ;

Holmgren, EB ;

Tobin, P ;

Sridhar, M ;

Hurwitz, HI ;

Kabbinavar, F ;

Novotny, WF ;

Hillan, KJ ;

Koeppen, H .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (13) :981-989

[8]

KASMAN I, 2008, P 100 ANN M AM ASS C

[9] Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab [J].

Khambata-Ford, Shirin ;

Garrett, Christopher R. ;

Meropol, Neal J. ;

Basik, Mark ;

Harbison, Christopher T. ;

Wu, Shujian ;

Wong, Tai W. ;

Huang, Xin ;

Takimoto, Chris H. ;

Godwin, Andrew K. ;

Tan, Benjamin R. ;

Krishnamurthi, Smitha S. ;

Burris, Howard A., III ;

Poplin, Elizabeth A. ;

Hidalgo, Manuel ;

Baselga, Jose ;

Clark, Edwin A. ;

Mauro, David J. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3230-3237

[10] Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [J].

Klement, G ;

Baruchel, S ;

Rak, J ;

Man, S ;

Clark, K ;

Hicklin, DJ ;

Bohlen, P ;

Kerbel, RS .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (08) :R15-R24

← 1 2 →